William Regine is a Radiation Oncologist in Baltimore, Maryland. Dr. Regine is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Pancreatic Cancer, Adult Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma, and Anal Cancer.

Dr. Jon Weingart focuses on the surgical treatment of brain tumors including benign and malignant tumors. Dr. Weingart also specializes in spinal disorders, such as cervical and lumbar disc disease, as well as other congenital and developmental abnormalities such as tethered spinal cord, spina bifida and chiari malformation. Dr. Weingart is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, Awake Craniotomy, and Osteotomy.

Dr. Kleinberg specializes in the radiation treatments, including stereotactic radiosurgery, of brain and spinal tumors. Areas of research include both tumors arising in the central nervous system and tumors metastasizing from other locations. He also specializes in the treatment of esophageal tumors and has led national clinical trials in both therapy of brain tumors as well as esophageal cancer. Dr. Kleinberg has been recently named in the US News and World Report list of top 1% of doctors in his specialty. He is the co-chair of the Eastern Cooperative Oncology Group Brain Tumor Working Group, Vice-Chair of the NCI Cooperative Group Steering Committee for Esophageal and Gastric Tumors, and is a member of the NCI Cooperative Group Steering Committee for Gastrointestinal Tumors. He is also on the American College of Radiation Oncology Neurologic Cancer Practice Accreditation Team. Make A Gift. Dr. Kleinberg is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Glioblastoma, Astrocytoma, Brain Tumor, Hepato-Pancreato-Biliary Surgery, and Gamma Knife Radiosurgery.

Dr. Matthias Holdhoff is a medical oncologist and co-director of the Brain Cancer Disease Group at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. He is a professor of oncology, neurology and neurological surgery at Johns Hopkins University School of Medicine. Dr. Holdhoff’s expertise is in primary brain cancers and central nervous system lymphomas. He earned his medical degree from Freie Universität Berlin, received his doctorate degree at Charité University Medicine Berlin. Dr. Holdhoff completed residency training in internal medicine at Johns Hopkins Bayview Medical Center, followed by a fellowship in medical oncology at Johns Hopkins Hospital with research training at the Ludwig Center for Cancer Genetics and Therapeutics (Kinzler-Vogelstein lab). As a clinical investigator in neuro-oncology, his research is focused on novel trials and translational biomarker studies in malignant gliomas and primary central nervous system lymphomas. He has led and contributed to numerous clinical trials, publications and presentations. Dr. Holdhoff serves as the director of the solid tumor inpatient service at the Sidney Kimmel Comprehensive Cancer Center. He is passionately involved in mentoring and teaching of fellows, residents and students. He is the director of the UCNS-certified neuro-oncology fellowship program at Johns Hopkins, and he is a teaching attending physician for the Osler internal medicine residency program. Dr. Holdhoff is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Glioma, Glioblastoma, Astrocytoma, and Brain Tumor.

Dr. Kristin Redmond specializes in the treatment of brain tumors and leads the spinal radiosurgery program. She received her undergraduate degree from Princeton University where she graduated magna cum laude with a focus in neuro-psychology. She attended medical school and obtained a Masters in Public Health in health systems management at Tulane University where she was elected to the Alpha Omega Alpha Honor Medical Society as well as the Gold Humanism in Medicine Honor Society. Dr. Redmonds research interest focuses on the development of novel radiation techniques and therapeutic agents to treat brain and spine tumors in order to increase tumor control and overall survival. In addition, she is working to develop innovative approaches to try to limit long term toxicities and minimize neuro-cognitive dysfunction following treatment for tumors of the central nervous system. Dr. Redmond believes in a holistic approach to medicine and feels that the social and psychological components of patient care are equally important to traditional therapies. She works closely with a team of specialists to support patients and families during their cancer journey. Make A Gift. Dr. Redmond is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). Her top areas of expertise are Chordoma, Brain Tumor, Astrocytoma, and Metastatic Brain Tumor.

Henry Brem is a Neurosurgery provider in Baltimore, Maryland. Dr. Brem is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Gliosarcoma, Glioma, Brain Tumor, Endoscopic Transnasal Transsphenoidal Surgery, and Osteotomy.

Stuart Grossman, M.D., is a professor of oncology at the Johns Hopkins Kimmel Cancer Center. He has served as Principal Investigator and Director of the Central Operations office of the National Cancer Institute-funded phase I/II brain tumor consortia (New Approaches to Brain Tumor Therapy CNS Consortium and the Adult Brain Tumor Consortium) for the past 22 years. He has led many phase I, II, and III institutional and cooperative group translational and clinical brain cancer research projects. Dr. Grossman's expertise is in brain cancers, translational and clinical research, and directing large, multicenter, multidisciplinary clinical trial groups and training programs. Dr. Grossman was an intern and resident at Strong Memorial Hospital in Rochester, NY, and a fellow at the Johns Hopkins University School of Medicine. He received his M.D. from the University of Rochester. Dr. Grossman is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, and Gliomatosis Cerebri.

Christopher Jackson is a neurosurgeon who specializes in brain tumors and cerebrovascular disorders, including glioma, meningioma, acoustic neuroma, trigeminal neuralgia, brain metastasis, arteriovenous malformation, and aneurysms. He is the director of the Acoustic Neuroma Center. Dr. Jackson earned his medical degree from the Johns Hopkins University School of Medicine, where he also completed his neurosurgical residency. During his residency, Dr. Jackson was honored with multiple distinctions, including the Frank L. Coulson Jr. Award for Clinical Excellence, the Irving J. Sherman Award for Resident Achievement, the Harvey Cushing Hunterian Research Award, and was elected to Alpha Omega Alpha. Dr. Jackson is an active researcher who has published over 35 peer-reviewed articles on brain tumor and cerebrovascular immunology. His laboratory focuses on how brain tumors evade the immune system and become resistant to immunotherapy. Additionally, Dr. Jackson’s laboratory explores the formation of cerebral aneurysms and inflammatory complications of cerebral aneurysm rupture. Dr. Jackson is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Trigeminal Neuralgia, Meningioma, Dysembryoplastic Neuroepithelial Tumors (DNET), Rhizotomy, and Microvascular Decompression.

David Kamson is an Oncologist in Baltimore, Maryland. Dr. Kamson is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Brain Tumor, Glioblastoma, Gliosarcoma, Metastatic Brain Tumor, and Hormone Replacement Therapy (HRT).

Dr. Jaishri Blakeley is the Marjorie Bloomberg Tiven Professor of Neurofibromatosis in Neurology, Oncology, and Neurosurgery at Johns Hopkins School of Medicine, director of the Johns Hopkins Comprehensive Neurofibromatosis Center and director of the Neurofibromatosis Therapeutic Acceleration Program (NTAP). She is an active clinician-scientist specializing in the care of people with NF1, NF2, LZTR1, SMARC1 schwannomatoses, and primary brain tumors. Her research expertise in the development of clinical trials for nervous system tumors and specifically, early clinical-translational studies including tumor pharmacokinetic and pharmacodynamic investigations, imaging biomarkers for rare nervous system tumors, and incorporation of patient-focused, functional endpoints into efficacy studies. She has been the national or international leader of 7 clinical trials focused on therapies for glioblastoma, NF1 and NF2. In 2012 she cofounded the NTAP to dramatically shift the landscape of NF1 via necessary, efficient, and expert discovery, translational and clinical research. NTAP focuses on therapeutics, fosters collaboration, facilitates open and timely sharing of results, and streamlines the research process to accelerate therapies for plexiform and cutaneous neurofibromas. Through NTAP, Dr. Blakeley has supported and collaborated with more than 80 laboratories and research teams across the globe enabling meaningful therapeutic development for NF1-associated neoplasms and supporting the development of an exceptional community of clinician scientists focused on NF1 via the Francis S. Collins Scholars Program in Neurofibromatosis Clinical and Translational Research. Her research and programmatic efforts are all in the service of improving outcomes for the patients with NF1, NF2, schwannomatosis, and primary brain cancer for whom she is honored to provide care. Dr. Blakeley is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). Her top areas of expertise are Neurofibromatosis, Schwannomatosis, Neurofibromatosis Type 2 (NF2), Neurofibromatosis Type 1 (NF1), and Laminectomy.

Mark Mishra is a Radiation Oncologist in Baltimore, Maryland. Dr. Mishra is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Metastatic Brain Tumor, Astrocytoma, Brain Tumor, Meningioma, and Prostatectomy. Dr. Mishra is currently accepting new patients.

Graeme Woodworth is a Neurosurgery provider in Baltimore, Maryland. Dr. Woodworth is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Glioblastoma, Astrocytoma, Brain Tumor, Awake Craniotomy, and Gastrostomy. Dr. Woodworth is currently accepting new patients.

Haroon Ahmad is a Neurologist in Baltimore, Maryland. Dr. Ahmad is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Oligodendroglioma, Glioma, Astrocytoma, and Glioblastoma.

John Laterra is a Neurologist in Baltimore, Maryland. Dr. Laterra is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, and Brain Tumor. Dr. Laterra is currently accepting new patients.

Dr. Daniel Laheru is a cancer specialist in Baltimore, caring for patients with pancreatic cancer, colorectal cancer and neuroendocrine cancers. Dr. Laheru serves as co-director of the Skip Viragh Center for Pancreas Cancer Clinical Research and Patient Care at Johns Hopkins Medicine. Dr. Laheru received his undergraduate degree in chemistry from The University of Utah. He earned his M.D. at Baylor College of Medicine. He completed his residency at The University of Utah Hospital and Clinics and performed a fellowship in medical oncology at The Johns Hopkins University School of Medicine and The Johns Hopkins Oncology Center. Dr. Laheru joined the Johns Hopkins faculty in 2001. Dr. Laheru's research interests include pancreatic cancer and chemotherapy resistance in pancreatic cancer. With Elizabeth Jaffee, M.D., he developed a vaccine that supercharges the immune system and causes immune cells, which tend to be tolerant of cancer, to seek out and kill pancreatic cancer cells throughout the body. He has given numerous invited talks on pancreatic cancer and other cancers both nationally and internationally. He has authored over 200 papers focused on pancreatic cancer. Dr. Laheru serves as associate editor of Annals of Pancreatic Cancer. He has been recognized by the American Society of Clinical Oncology with the Young Investigator Award, by the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins as an Isaac and Catharine Hecht Scholar and has been elected to the Miller-Coulson Academy of Clinical Excellence. He is a member of the American College of Physicians, the American Society of Clinical Oncology and the American Association for Cancer Research. Dr. Laheru is rated as an Advanced provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Pancreatic Cancer, Familial Pancreatic Cancer, Neuroendocrine Tumor, Pancreaticoduodenectomy, and Pancreatectomy.

Karisa Schreck is co-director of the BRAF Brain Tumor Center at Johns Hopkins. Her research focuses on the development of small-molecule targeted therapies for patients with primary brain tumors. Dr. Schreck has specific expertise in the treatment of BRAF gene mutations. As such, she works with Christine Pratilas’ laboratory to investigate resistance mechanisms to BRAF-targeted therapy. Dr. Schreck also writes and runs clinical trials for novel targeted agents through the Comprehensive Brain Tumor Center and the Alliance for Clinical Trials in Oncology. Dr. Schreck is rated as an Advanced provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). Her top areas of expertise are Glioma, Brain Tumor, Astrocytoma, and Glioblastoma.

Dr. Lipson is an internationally-recognized skin cancer and immunotherapy specialist at Johns Hopkins. He received his medical degree in 2005 from the Mount Sinai School of Medicine in New York City, where he graduated with distinction in research. He completed his internship and residency in Internal Medicine at The Johns Hopkins Hospital, and completed a Medical Oncology fellowship at the Johns Hopkins Kimmel Cancer Center. Dr. Lipson leads cutting edge clinical trials for patients with melanoma and other skin cancers. As a member of the Johns Hopkins Melanoma and Cancer Immunology Programs, he focuses on evaluating novel therapies for patients with high-risk or advanced disease. Dr. Lipson’s publications include the first reports of organ transplant recipients treated with immune checkpoint inhibitors for advanced cancer, and the first description of kidney retransplantation performed after immunotherapy–related organ rejection. Based on his published work, Dr. Lipson initiated a clinical trial testing a novel combination of immune-based therapies for kidney transplant recipients with advanced selected cancers. Results from this trial - the first of its kind - were reported in 2022 at an international oncology meeting. Dr. Lipson is a leader in the clinical development of relatlimab, an antibody blocking the LAG-3 immune checkpoint. He leads a phase 2 trial testing combination immune checkpoint inhibitor therapy—including anti-LAG-3—for patients with advanced basal cell carcinoma. In June 2021, Dr. Lipson presented findings from the first phase 3 study establishing the LAG-3 pathway as the third immune checkpoint pathway in history, after CTLA-4 and PD-1, for which blockade has clinical benefit. This trial supported the FDA's approval of a new therapy for patients with advanced melanoma. In addition to his research activities, Dr. Lipson is an educator in the field of cancer immunotherapy. Many of his lectures focus on the management of immune-mediated drug toxicities associated with novel cancer drugs. Dr. Lipson conducts regular clinical practices in Baltimore, Maryland and at Sibley Memorial Hospital in Washington, D.C. as part of the multidisciplinary Melanoma Program at Johns Hopkins. Dr. Lipson is rated as an Experienced provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Melanoma, Merkel Cell Carcinoma, Melanoma of the Eye, Metastatic Uveal Melanoma, and Pancreaticoduodenectomy.

Maria Jacobs is a Radiation Oncologist in Baltimore, Maryland. Dr. Jacobs is rated as an Advanced provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). Her top areas of expertise are Breast Cancer, Familial Prostate Cancer, Prostate Cancer, and Neuroendocrine Carcinoma of the Cervix. Dr. Jacobs is currently accepting new patients.

Charles Park is a Neurosurgery provider in Baltimore, Maryland. Dr. Park is rated as an Advanced provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Invertebral Disc Disease, Cervical Myelopathy, Cervical Spondylosis, Microdiscectomy, and Herniated Disc Surgery. Dr. Park is currently accepting new patients.

Elizabeth Nichols is a Radiation Oncologist in Baltimore, Maryland. Dr. Nichols is rated as an Advanced provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). Her top areas of expertise are Breast Cancer, Angiosarcoma, Cervical Cancer, and Adult Soft Tissue Sarcoma.